Clinical Trials Logo
  1. Home
  2. HPV Infections
  3. NCT03900572

A Study of Safety and Primary Immunogenicity of 9-valent HPV Recombinant Vaccine

HPV Infections Clinical Trial

Official title:
A Randomized, Double-Blind and Placebo-Controlled Phase I Study to Evaluate the Safety and Immunogenicity of a 9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52 and 58) Recombinant Vaccine (Pichia Pastoris) in 9 to 45 Year Old Chinese Females

Clinical Trial Summary

A randomized, double-blind and placebo-controlled phase I study to evaluate the safety and immunogenicity of a 9-valent Human Papillomavirus (HPV) vaccine, administered intramuscularly according to a 0, 2, 6-month schedule in 9 to 45 years old healthy Chinese females.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03900572
Study type Interventional
Source Shanghai Zerun Biotechnology Co.,Ltd
Contact
Status Completed
Phase Phase 1
Start date March 9, 2019
Completion date April 30, 2020
View Details
See also
  Status Clinical Trial Phase
Completed NCT00956553 - Reactogenicity Study of Cervarix and Gardasil in UK Adolescent Girls Phase 4
Completed NCT05372016 - Evaluate the Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females Phase 3
Recruiting NCT05027776 - Immunogenicity and Safety of Quadrivalent HPV Vaccine in Healthy Chinese Female Subjects Aged 9 to 19 Years Phase 3
Suspended NCT00733122 - Tolerability and Immunogenicity of Gardasil in Females Between 16 and 23 Years of Age in India (V501-034) Phase 3
Recruiting NCT04895020 - Immunobridging Study of 9-valent Human Papillomavirus Recombinant Vaccine in Chinese Females Aged 9 to 19 Years Phase 3
Recruiting NCT05371353 - Immune Persistence After the Whole Vaccination Shcedule With Recombination Quadrivalent HPV Vaccine
Completed NCT00635830 - An Open-Label, Single Dose Safety Study of Quadrivalent HPV Vaccine in Chinese Female Subjects (V501-035) Phase 1
Not yet recruiting NCT01021904 - Primary and Secondary Prevention of Human Papillomavirus (HPV) Disease in China Phase 4
Completed NCT00378560 - V501 Efficacy Study in Women Aged 18 to 26 (V501-027) Phase 2
Completed NCT00682812 - Significance of the High-risk Hpv Viral Load N/A
Completed NCT01086709 - Crossover Vaccination of Women Previously Randomized Into Protocol 04-C-N191
Completed NCT00711815 - A Study to Identify Markers in Blood and Tissue of HPV Clearance N/A
Completed NCT00834106 - Prevention of Human Papillomavirus (HPV) in 20 to 45 Year Old Chinese Women (V501-041) Phase 3
Completed NCT03085381 - A Phase I Study of Quadrivalent HPV Recombinant Vaccine Phase 1
Completed NCT00847340 - Human Papillomavirus (HPV) Genotypes in Genital Warts in Colombian Population N/A
Completed NCT00411749 - V501 Immunogenicity Study in Females Age 9 to 17 Years (V501-028) Phase 2
Completed NCT00943722 - A Study of V503 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in Preadolescents and Adolescents (V503-002) Phase 3